Thelansis

  Fibrocystic breast disease (FCD), a prevalent non-cancerous condition affecting many women globally, falls under benign breast diseases. These conditions encompass non-malignant abnormalities such as tumors, trauma, mastalgia, and nipple discharge. The development of benign breast disease is closely associated with the use of estrogen and anti-estrogen therapies in women. The process of mammary gland development, maturation, and differentiation is influenced by hormonal and growth factor changes, which impact the stromal and epithelial cells. During the late proliferative phase, the glandular tissue may progress to hyperplastic stages like sclerosing adenosis or lobular hyperplasia. Hyperplasia, particularly when associated with a 2% prevalence of Ki67 cells, indicates a twofold increased risk of developing breast cancer. Proliferative lesions exhibit a 1.3 to 1.9 times higher likelihood of malignancy in both breasts. Consequently, any increase in pleomorphic calcifications obs...

 Fibrocystic Breast Disease (FCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032 Description: Indication name: Fibrocystic Breast Disease (FCD) ·        Fibrocystic breast disease (FCD), a prevalent non-cancerous condition affecting many women globally, falls under benign breast diseases. These conditions encompass non-malignant abnormalities such as tumors, trauma, mastalgia, and nipple discharge. The development of benign breast disease is closely associated with the use of estrogen and anti-estrogen therapies in women. The process of mammary gland development, maturation, and differentiation is influenced by hormonal and growth factor changes, which impact the stromal and epithelial cells. During the late proliferative phase, the glandular tissue may progress to hyperplastic stages like sclerosing adenosis or lobular hyperplasia. Hyperplasia, particularly when associated with a 2% prevalence o...